Many high-risk medical devices earn US marketing approval based on limited premarket clinical evaluation that leaves important questions unanswered. Rigorous postmarket surveillance includes registries that actively collect and maintain information defined by individual patient exposures to particular devices. Several prominent registries for cardiovascular devices require enrolment as a condition of reimbursement for the implant procedure, without informed consent. In this article, we focus on whether these registries, separate from their legal requirements, have an ethical obligation to obtain informed consent from enrolees, what is lost in not doing so, and the ways in which seeking and obtaining consent might strengthen postmarket surveillance in the USA.
- clinical ethics
Data availability statement
No data are available/not applicable.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Contributors Both authors contributed equally to the conception, drafting and revision of this manuscript and approve its final form.
Funding DK is supported in part by the Greenwall Faculty Scholars Program in Bioethics. DK also reports serving as a consultant to the Circulatory Systems Advisory Panel of the Food and Drug Administration, and to Firefly Health.
Competing interests This work was supported by the Greenwall Foundation.
Provenance and peer review Not commissioned; externally peer reviewed.
Read the full text or download the PDF:
Other content recommended for you
- A systematic review of ICD complications in randomised controlled trials versus registries: is our ‘real-world’ data an underestimation?
- Influence of healthy candidate bias in assessing clinical effectiveness for implantable cardioverter-defibrillators: cohort study of older patients with heart failure
- Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006–2021: a cross-sectional study
- Implantable cardioverter defibrillators: risks accompany the life-saving benefits
- The FDA approval process for medical devices: an inherently flawed system or a valuable pathway for innovation?
- Familial risk of atrioventricular block in first-degree relatives
- Quality of evidence behind FDA approvals varies widely
- Cardiac implant registries 2006–2016: a systematic review and summary of global experiences
- Safety of serial MRI in patients with implantable cardioverter defibrillators
- Identifying optimal postmarket surveillance strategies for medical and surgical devices: implications for policy, practice and research